PT-141, also known as Bremelanotide, is a synthetic peptide that acts on melanocortin receptors, a group of receptors involved in several biological processes, including sexual responses. Unlike treatments that primarily influence blood flow, bremelanotide acts through signalling pathways in the nervous system. This has made it an important subject of research into sexual desire, brain signalling, and the biological regulation of sexual function.

Research has examined how bremelanotide influences signals in the brain associated with sexual interest and arousal. Sexual function involves a complex interaction between hormones, nerve signals, emotional factors, and physical responses. Bremelanotide's activity at melanocortin receptors has helped researchers investigate how the nervous system contributes to sexual desire, particularly in women experiencing certain forms of reduced sexual interest.

Bremelanotide has progressed through human clinical trials involving women with acquired, generalized hypoactive sexual desire disorder (HSDD), a condition involving persistently low sexual desire that causes personal distress. Clinical research demonstrated improvements in certain measures of sexual desire and related distress, leading to FDA approval of a specific bremelanotide medicine for eligible premenopausal women.

Although bremelanotide has an established clinical research history, its approved use is limited to a specific condition and patient population. Research findings do not establish that it improves sexual function in everyone or that all formulations have equivalent safety and effectiveness. Continued research may help clarify its broader biological effects, limitations, and long-term clinical significance.